Biopharma | May 05, 2026
Swiss Biotech Association reports CHF 7.5 billion revenue for Switzerland’s biotech Industry in 2025
The private funding rose 38% amid growing international collaborations and CDMO demand
The private funding rose 38% amid growing international collaborations and CDMO demand
Funds to support product expansion, quick commerce growth, and manufacturing scale-up for holistic period care solutions
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
Researchers say simple blood-test and echocardiography pathway could reshape diabetes-related cardiovascular care
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Heart failure affects an estimated 64.3 million people worldwide
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
Subscribe To Our Newsletter & Stay Updated
